Added to YB: 2026-10-08
Pitch date: 2026-10-04
BDTX [bullish]
Black Diamond Therapeutics, Inc.
-8.42%
current return
Author Info
No bio for this author
Company Info
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
Market Cap
$101.7M
Pitch Price
$1.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.19
P/E
-2.38
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Black Diamond Therapeutics, Inc.
BDTX (quick overview): Black Diamond is a $1.86 mutation-defined oncology bet centered on BDTX-1535 and its RAF franchise, targeting EGFR and RAS settings where existing kinase inhibitors leave known resistance gaps. Strategic value would come from a focused line extension rather than broad platform novelty, but the program must demonstrate durable activity in defined mutation populations and differentiated tolerability versus previous agents.
Read full article (1 min)